Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03148418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 87 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion moved earlier from Dec 31, 2026 to Nov 30, 2026 Eligibility criteria expanded, about 13 words · Site details revised at 8 of 170 sites Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Site details revised at 8 of 170 sites
  2. Primary and study completion moved earlier from Mar 6, 2030 to Dec 31, 2026v86
  3. 2 versions Re-verified since Jan 12, 2026, no change to tracked fieldsv84-v85
  4. Secondary endpoints: details revised at 1 of 3 entriesv83
  5. Study sites revised (170)v82 See this version in full on ClinicalTrials.gov ↗
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites: 171 to 170v81
  2. Study sites: 170 to 171v80
  3. Study sites: 173 to 170v79
  4. Re-verified, no change to tracked fieldsv78
  5. Site details revised at 1 of 173 sitesv77
  6. Study sites revised (173)v76 See this version in full on ClinicalTrials.gov ↗
  7. Study sites revised (173)v75 See this version in full on ClinicalTrials.gov ↗
  8. Interventions: Atezolizumab (Drug) to Atezolizumab (Drug), Bevacizumab (Drug) Site details revised at 1 of 173 sites · Study arms: 1 to 3v74 Show 2 more changesShow less
    • Site details revised at 1 of 173 sites
    • Study arms: 1 to 3
  9. Study sites revised (173)v73 See this version in full on ClinicalTrials.gov ↗
  10. Phase: Phase 4 to Phase 3 Site details revised at 2 of 173 sitesv72 Show 1 more changeShow less
    • Site details revised at 2 of 173 sites
  11. Study sites revised (173)v71 See this version in full on ClinicalTrials.gov ↗
  12. Site details revised at 2 of 173 sitesv70
  13. Re-verified, no change to tracked fieldsv69
  14. Enrollment target: 387 to 382v68
  15. Re-verified, no change to tracked fieldsv67
  16. Enrollment target: 389 to 387v66
  17. 3 versions Re-verified since Nov 18, 2021, no change to tracked fieldsv63-v65
  18. Study sites: 172 to 173v62
  19. Re-verified, no change to tracked fieldsv61
  20. Site details revised at 2 of 172 sitesv60
  21. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 380 to confirmed 389 · Study sites: 215 to 172v59 Show 2 more changesShow less
    • Enrollment target: estimated 380 to confirmed 389
    • Study sites: 215 to 172
  22. Study sites revised (215)v58 See this version in full on ClinicalTrials.gov ↗
  23. Site details revised at 1 of 215 sitesv57
  24. Site details revised at 8 of 215 sitesv56
  25. Site details revised at 6 of 215 sitesv55
  26. Site details revised at 8 of 215 sitesv54
  27. Study sites revised (215)v53 See this version in full on ClinicalTrials.gov ↗
  28. Phase: Phase 3 to Phase 4 Site details revised at 2 of 215 sitesv52 Show 1 more changeShow less
    • Site details revised at 2 of 215 sites
  29. Site details revised at 19 of 215 sitesv51
  30. Site details revised at 18 of 215 sitesv50
  31. Study sites revised (215)v49 See this version in full on ClinicalTrials.gov ↗
  32. Site details revised at 2 of 215 sitesv48
  33. Study sites: 216 to 215v47
  34. Site details revised at 5 of 216 sitesv46
  35. Site details revised at 2 of 216 sitesv45
  36. Enrollment target: 546 to 380 Study sites revised (216)v44 Show 1 more changeShow less
    • Study sites revised (216)

    See this version in full on ClinicalTrials.gov ↗

  37. Site details revised at 1 of 216 sitesv43
  38. Study sites: 214 to 216v42
  39. Study sites: 213 to 214v41
  40. Study sites: 212 to 213v40
  41. Primary and study completion dates: Aug 5, 2027 to Mar 6, 2030 Site details revised at 2 of 212 sitesv39 Show 1 more changeShow less
    • Site details revised at 2 of 212 sites
  42. Site details revised at 7 of 212 sitesv38
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.
Trial Details
NCT Number NCT03148418
Lead Sponsor Hoffmann-La Roche
Conditions Cancer
Enrollment 382 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov